Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/24/21 | $60,000,000 | Series B |
Access Biotechnology Acorn Bioventures Intermediate Capital Group  LifeArc RA Capital Management Samlyn Capital | undisclosed |
